Pediatric Adhd Articles & Analysis: Older
9 news found
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD). The trial will enroll ...
The multicenter trial will enroll up to 150 children with moderate to severe ADHD and randomize them to receive active or sham eTNS for a four-week blinded period. ...
“With an FDA clearance for pediatric ADHD and now Breakthrough Device Designation for DRE, NeuroSigma continues to demonstrate the Monarch eTNS System is a safe and effective alternative to drug-based or surgical treatments for an expanding number of serious diseases,” commented Tom Paschall, Director of NeuroSigma. ...
NeuroSigma, Inc., a bioelectronic medical device company, and Ignis Therapeutics, a life science company focusing on the central nervous system therapies, jointly announced today that Ignis Therapeutics has acquired the exclusive license in China (including Hong Kong and Macau) of NeuroSigma’s Monarch eTNS System® to treat attention deficit hyperactivity disorder ...
NeuroSigma is the developer of the Monarch eTNS System®, which uses non-invasive, external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric indications, including ADHD, depression, and drug resistant epilepsy. The therapy is the first device-based, non-drug therapy approved by the FDA to treat pediatric ADHD. ...
NeuroSigma is the developer of the Monarch eTNS System®, which uses non-invasive external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric indications, including ADHD, depression, and epilepsy. The therapy is the first device-based, non-drug therapy approved by the FDA to treat pediatric ADHD. ...
KT Corporation and NeuroSigma, Inc. jointly announced signing of a memorandum of understanding, forming a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy. NeuroSigma is the developer of the Monarch eTNS System®, which uses ...
"We now have in place the requisite building blocks needed for a successful commercial launch in the US of the Monarch system to treat pediatric ADHD, namely the patents, FDA clearance and CMS Level II HCPCS codes," added Ekchian. Background – eTNS In the United States NeuroSigma's Monarch eTNS System is indicated for the treatment of ...
James McGough, lead investigator of the pivotal eTNS ADHD trial conducted at UCLA, for his assistance during the CMS review process," said Leon Ekchian, Ph.D., President & CEO of NeuroSigma. "NeuroSigma's Monarch eTNS System was the first non-drug treatment for pediatric ADHD cleared by the FDA. Starting April 1st of this year, payers will ...